We design and engineer streamlined microbial genomes through systematic reduction and functional optimization. Enginoma combines computational genome analysis with synthetic biology to create efficient minimal chassis organisms.
Native microbial genomes contain numerous non-essential genes that consume cellular resources without contributing to production. Systematic genome reduction creates streamlined chassis organisms with improved resource allocation and stability.
Eliminating non-essential genetic burden redirects cellular resources toward heterologous production. Reduced genomes show improved expression yields and metabolic efficiency for target compounds.
Streamlined genomes exhibit improved genetic stability with reduced rearrangements and horizontal gene transfer. Stable chassis organisms maintain production consistency across extended fermentation cycles.
Reduced genomes simplify regulatory pathways and reduce unpredictable metabolic interactions. This enables more predictable and controllable cellular factories.
Minimized chassis demonstrate superior performance in large-scale fermentation. Simplified backgrounds reduce process variability and improve overall bioprocess economics.
From essential gene analysis to synthetic genome design, our platform covers the complete minimal genome development workflow.
Systematic identification of essential and non-essential genes through transposon sequencing and comparative genomics. Our analysis prioritizes gene clusters for safe elimination while preserving core cellular functions.
Multi-stage genome reduction combining iterative deletion approaches with SCRaMbLE for rapid genome streamlining. We balance reduction extent with strain robustness requirements.
Strategic reintroduction of essential biosynthetic functions into minimized genomes. We design minimal synthetic gene circuits that restore or enhance production capabilities.
Comprehensive genome minimization services across diverse microbial platforms
E. coli and model bacteria
Systematic reduction of bacterial genomes inspired by JCVI-syn3.0 design principles. We identify and eliminate non-essential genetic elements while preserving core cellular machinery.
S. cerevisiae Sc3.0 platform
SCRaMbLE-mediated genome reduction for yeast chassis optimization. The synthetic chromosome platform enables rapid combinatorial genome restructuring with phenotype selection.
De novo chromosome construction
Design and synthesis of minimal artificial chromosomes with precisely defined gene content. Our platform enables bottom-up construction of streamlined genomic platforms.
Production-ready strains
Integration of genome minimization with metabolic engineering for optimized production strains. We combine reduction strategies with pathway optimization for enhanced bioproduction.
Integrated computational design followed by iterative experimental validation
We analyze your host genome to identify essential, non-essential, and quasi-essential genes. Comparative genomics with reference minimal genomes guides deletion strategy design.
Our computational models prioritize gene clusters for safe elimination while maintaining strain robustness. We design sequential deletion strategies that balance reduction extent with viability.
Iterative genome reduction using CRISPR-Cas systems and SCRaMbLE. Each deletion stage is validated for growth, genetic stability, and production capability.
Comprehensive characterization of reduced strains including growth profiling, stress tolerance, genetic stability, and production performance validation.
Minimal genome chassis for optimized bioproduction across diverse markets
Streamlined chassis for enhanced production of therapeutic proteins, industrial enzymes, and vaccine components with improved yield and purity profiles.
Minimal chassis optimized for biosynthesis of pharmaceuticals, nutraceuticals, and specialty chemicals through metabolic pathway integration.
Efficient microbial platforms for sustainable production of ethanol, butanol, and advanced biofuels with improved carbon yields.
Simplified genetic backgrounds for construction of robust biosensor strains with predictable performance characteristics.
Safe, genetically minimal chassis for engineered probiotic and living medicine applications with reduced horizontal gene transfer risk.
Characterized minimal backgrounds for standardized synthetic biology part testing and genetic circuit development.
Our pipeline builds on peer-reviewed methods published in leading journals
Hutchison, C.A. et al. Design and synthesis of a minimal bacterial genome. Science 351, aad6253 (2016). https://doi.org/10.1126/science.aad6253
JCVI-syn3.0: design and synthesis of a minimal bacterial genome with 473 genes.Jiang, S. et al. Building a eukaryotic chromosome arm by de novo design and synthesis. Nat Commun 14, 7886 (2023). https://doi.org/10.1038/s41467-023-43531-5
De novo design and synthesis of a synthetic yeast chromosome arm.Blount, B.A. et al. Trimming the genomic fat: minimising and re-functionalising genomes using synthetic biology. Nat Commun 14, 1984 (2023). https://doi.org/10.1038/s41467-023-37748-7
Comprehensive review of genome minimization strategies and re-functionalization approaches.Ravagnan, G. & Schmid, J. Promising non-model microbial cell factories obtained by genome reduction. Front Bioeng Biotechnol 12, 1427248 (2024). https://doi.org/10.3389/fbioe.2024.1427248
Genome reduction strategies for non-model industrial microorganisms.Dai, J. et al. Sc3.0: revamping and minimizing the yeast genome. Genome Biol 21, 205 (2020). https://doi.org/10.1186/s13059-020-02134-9
Design and construction of Sc3.0 synthetic yeast genome with systematic removals.We work with E. coli, Saccharomyces cerevisiae, Bacillus subtilis, and other model and non-model bacteria. Our platform adapts to organism-specific genetic tools and essential gene requirements.
Reduction extent depends on host organism and application requirements. E. coli can typically be reduced by 15-30% while maintaining robust growth. Yeast reduction targets depend on synthetic chromosome availability.
Reduced genomes show improved expression yields, enhanced genetic stability, reduced metabolic burden, and more predictable cellular behavior. These advantages translate to more consistent bioprocess performance.
Yes. We integrate genome minimization with metabolic pathway optimization to create production-optimized chassis strains. Our platform designs reduction strategies that complement production requirements.
We perform comprehensive characterization including growth profiling, stress tolerance, genetic stability assessment, and production performance validation under relevant fermentation conditions.
Our team combines computational genome analysis with synthetic biology to design streamlined microbial chassis for your production needs.
Tell us about your project and we'll get back within 24 hours.
